LLY · News · 20260831N

Acquisition Activity and IPR&D

ELI LILLY & Co · 2026-08-31 · Importance 71 · Surprise 60

Eli Lilly agreed on August 31, 2026, to acquire privately held Merida Biosciences for up to approximately $2.88 billion in cash, exceeding the company’s materiality threshold. The transaction expands Lilly’s immunology pipeline and adds Merida’s antibody-engineering platform, which is intended to remove disease-causing antibodies while preserving normal immune function. Merida’s lead program, MER511, has generated initial Phase 1 data showing robust reductions in pathogenic thyroid-stimulating antibodies and a favorable initial safety profile.

Key facts

• Proactive Investors reported Eli Lilly will acquire Merida Biosciences for up to $2.88 billion in cash as part of a deal-making push to broaden its treatments for immune-related and allergic diseases. source
• Eli Lilly said the acquisition of Merida strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need. source
• Merida's antibody-engineering platform is described in Lilly's announcement as designed to enable precise, durable removal of disease-causing antibodies while preserving normal immune function. source
• Initial Phase 1 data reported in the announcement show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile. source
• Proactive Investors said the acquisition continues a run of dealmaking for Lilly, whose deal spending this year has outpaced prior years as it looks to diversify beyond its obesity and diabetes franchises. source